1) Loughrey JPR, Smith HS. Anticonvulsant drugs in the treatment of chronic pain states. In:Smith HS (ed). Drugs for Pain. Philadelphia:Hanley & Belfus Inc;2003.p.165-82.
2) Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain:Evidence-based recommendations. Pain 2007;132:237-51.
3) Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain:2010 revision. Eur J Neurol 2010;17:1113-23.
4) Moulin DE, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain:Revised consensus statement from the Canadian Pain Society. Pain Res Manag 2014;19:328-35.
5) Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults:a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73.
6) Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain 2010;150:573-81.
7) 日本ペインクリニック学会神経障害性疼痛薬物療法ガイドライン改訂版作成ワーキンググループ(編).神経障害性疼痛薬物療法ガイドライン改訂第2版.東京:真興交易;2016.
8) 日本神経治療学会治療指針作成委員会.標準的神経治療:慢性疼痛.神経治療2010;27:591-622.
9) Baron R, Binder A, Attal N, et al. Neuropathic low back pain in clinical practice. Eur J Pain 2016;20:861-73.
10) 益田律子.ガバペンチンとプレガバリン.臨床麻酔2011;35臨増:445-60.
11) 加藤信也,益田律子.抗てんかん薬.ペインクリニック2009;30別冊:S212-23.